357 related articles for article (PubMed ID: 26791999)
1. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Hecker J; Marten S; Keller L; Helmert S; Michalski F; Werth S; Sahin K; Tittl L; Beyer-Westendorf J
Thromb Haemost; 2016 May; 115(5):939-49. PubMed ID: 26791999
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Beyer-Westendorf J; Ebertz F; Förster K; Gelbricht V; Michalski F; Köhler C; Werth S; Endig H; Pannach S; Tittl L; Sahin K; Daschkow K; Weiss N
Thromb Haemost; 2015 Jun; 113(6):1247-57. PubMed ID: 25739533
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry.
Helmert S; Marten S; Mizera H; Reitter A; Sahin K; Tittl L; Beyer-Westendorf J
J Thromb Thrombolysis; 2017 Aug; 44(2):169-178. PubMed ID: 28643004
[TBL] [Abstract][Full Text] [Related]
4. Patterns of atrial fibrillation anticoagulation with rivaroxaban - 7-year follow-up from the Dresden NOAC registry.
Tittl L; Marten S; Naue C; Beyer-Westendorf J
Thromb Res; 2024 Apr; 236():61-67. PubMed ID: 38394987
[TBL] [Abstract][Full Text] [Related]
5. 5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry.
Tittl L; Marten S; Naue C; Beyer-Westendorf J
Thromb Res; 2021 Jun; 202():24-30. PubMed ID: 33711755
[TBL] [Abstract][Full Text] [Related]
6. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry.
Beyer-Westendorf J; Förster K; Ebertz F; Gelbricht V; Schreier T; Göbelt M; Michalski F; Endig H; Sahin K; Tittl L; Weiss N
Europace; 2015 Apr; 17(4):530-8. PubMed ID: 25694537
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
8. Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY.
Köhler C; Tittl L; Marten S; Naue C; Spindler M; Stannek L; Fache K; Beyer-Westendorf J
Thromb Res; 2022 Jul; 215():37-40. PubMed ID: 35623105
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.
Hankey GJ; Patel MR; Stevens SR; Becker RC; Breithardt G; Carolei A; Diener HC; Donnan GA; Halperin JL; Mahaffey KW; Mas JL; Massaro A; Norrving B; Nessel CC; Paolini JF; Roine RO; Singer DE; Wong L; Califf RM; Fox KA; Hacke W;
Lancet Neurol; 2012 Apr; 11(4):315-22. PubMed ID: 22402056
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
[TBL] [Abstract][Full Text] [Related]
14. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
Spencer RJ; Amerena JV
Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
[TBL] [Abstract][Full Text] [Related]
16. Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Chen ST; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
Am J Cardiol; 2017 Nov; 120(10):1837-1840. PubMed ID: 28886856
[TBL] [Abstract][Full Text] [Related]
17. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
Fox KA; Piccini JP; Wojdyla D; Becker RC; Halperin JL; Nessel CC; Paolini JF; Hankey GJ; Mahaffey KW; Patel MR; Singer DE; Califf RM
Eur Heart J; 2011 Oct; 32(19):2387-94. PubMed ID: 21873708
[TBL] [Abstract][Full Text] [Related]
18. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
[TBL] [Abstract][Full Text] [Related]
19. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
Yasaka M; Minematsu K; Toyoda K; Yamagami H; Yoshimura S; Nagao T; Mori E; Hirano T; Hamasaki T; Yamaguchi T
J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1342-8. PubMed ID: 26987488
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial.
Sherwood MW; Nessel CC; Hellkamp AS; Mahaffey KW; Piccini JP; Suh EY; Becker RC; Singer DE; Halperin JL; Hankey GJ; Berkowitz SD; Fox KAA; Patel MR
J Am Coll Cardiol; 2015 Dec; 66(21):2271-2281. PubMed ID: 26610874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
